Successful Antithrombin Administration in Andexanet Alfa-Associated Heparin Resistance
During routine CPB, high-dose unfractionated heparin (UFH) prevents consumptive coagulopathy and the formation of thrombi within the CPB circuit and the patient's circulation. Prior treatment with andexanet alfa can pose difficulties in achieving adequate anticoagulation during CPB with UFH. The administration of antithrombin, in combination with UFH, may overcome these difficulties.
